Pricing Log in Create free account
Saturday 17 October 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

DexCom, Inc. 10-K filed Feb 12, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:20 PM ET · Document on sec.gov · Filing index

Red flags

  • Auditor change

    DexCom, Inc. changed auditor from Ernst & Young LLP to Deloitte & Touche LLP

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 18, 2025: 15 added · 1 removed · 124 modified; 5 with only figures updated; 15 moved without change

140 more changes in this Item, word by word, in Powerpack.

Powerpack